Evaluation of the carcinogenic potential of pharmaceuticals. Opportunities arising from the International Conference on Harmonisation

Drug Safety

Volumn 18, Issue 5, 1998, Pages 309-319

  Monro, Alastair M ^a   MacDonald, James S ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUSULFAN; CARCINOGEN; CHLORAMBUCIL; CHLORNAPHAZINE; COAL TAR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LOMUSTINE; MELPHALAN; METHOXSALEN; PHENACETIN; PREDNISONE; PROCARBAZINE; STEROID HORMONE; THIOTEPA; TREOSULFAN; VINCRISTINE;

ADRENAL CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BLADDER CANCER; BREAST CANCER; CARCINOGENICITY; COLON CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDUSTRY; DRUG SAFETY; GENOTOXICITY; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TARGET ORGAN; TESTIS CANCER; THYROID CANCER; TISSUE INJURY; TRANSGENIC MOUSE;

ANIMALS; CARCINOGENICITY TESTS; EUROPEAN UNION; HUMANS; INTERNATIONAL COOPERATION; JAPAN; MICE; PHARMACEUTICAL PREPARATIONS; RATS; UNITED STATES;

EID: 0031970720     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818050-00001     Document Type: Article

References (39)

1. D'Arcy PF, Harron DWG, editors. Proceedings of the Third International Conference on Harmonisation; Nov 1995: Yokohama, Japan. Belfast: Queen's University Press, 1996
2. Ashby J, Tennant RW. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP. Mutat Res 991; 257: 229-306
3. Gold LS, Bernstein L, Magaw R, et al. Inter-species extrapolation in carcinogenesis: prediction between rats and mice. Environ Health Perspect 1989; 81: 211-9
4. Monro AM. Testing for carcinogenic potential. In: D'Arcy PF, Harron DWG, editors. Proceedings of the Third International Conference on Harmonisation; Nov 1995: Yokohama, Japan. Belfast: Queen's University Press, 1996: 261-8
5. van Oosterhout JPJ, van der Laan JW, de Waal EJ, et al. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Pharmacol Toxicol 1997; 25: 6-17
6. Contrera JF, Jacobs AC, DeGeorge JJ. Carcinogenicity testing and the evaluation of the regulatory requirements for pharmaceuticals. Regul Pharmacol Toxicol 1997; 25: 130-45
7. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA 1995; 92: 5258-65
8. Monro AM. Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Exp Toxicol Pathol 1996; 48: 155-66
9. Cancer facts and figures, Atlanta (GA): American Cancer Society, 1995
10. Davies TS, Monro AM. Marketed human pharmaceuticals reported to be tumorigenic in rodents. J Am Coll Toxicol 1995; 14: 90-107
11. Haseman JK. Patterns of tumor incidence in two-year cancer bioassay feeding studies in Fischer 344 rats. Fundam Appl Toxicol 1983; 3: 1-9
12. Davies TS, Monro AM. The rodent carcinogenicity bioassay produces a similar frequency of tumor increases and decreases: implications for risk assessment. Regul Toxicol Pharmacol 1994; 20: 281-301
13. Ames BN, Gold LW. Too many rodent carcinogens: mitogenesis increases carcinogenesis. Science 1990; 249: 970-1
14. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990; 249: 1007-11
15. Clayson DB, Iverson F, Mueller R. An appreciation of the maximum tolerated dose: an inadequately precise decision point in designing a carcinogenesis bioassay? Teratog Carcinog Mutagen 1991; 11: 279-96
16. Grasso P, Sharrat M, Cohen AJ. Role of persistent, non-genotoxic tissue damage in rodent cancer and relevance to humans. Annu Rev Pharmacol Toxicol 1991; 31: 253-87
17. Monro AM. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans. Adverse Drug React Toxicol Rev 1993; 12: 5-34
18. Cohen SM. Human relevance of animal carcinogenicity studies. Regul Toxicol Pharmacol 1995; 21: 75-80
19. Goodman JI. A rational approach to risk assessment requires the use of biological information: an analysis ot the National Toxicology Program (NTP), final report of the advisory review by the NTP Board of Scientific Counsellors. Regul Toxicol Pharmacol 1994; 19: 51-9
20. Gori GB, Flamm WG. How sick a patient? Report of a workshop on cancer risk assessment. Regul Toxicol Pharmacol 1991; 14: 215-22
21. Marselos M, Vainio H. Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme. Carcinogenesis 1991; 12: 1751-6
22. Ashby J, Paton D. The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures. Mutat Res 1993; 286: 3-74
23. Monographs on the evaluation of the carcinogenic risk to humans. International Agency for Research on Cancer, Lyon; 64: 1996
24. Williams GM, Weisburger JH. Chemical carcinogenesis. In: Amdur MO, Doull J, Klaassen CD, editors. Casarett and Doull's toxicology. 4th ed. New York: Pergamon Press, 1991: 127-200
25. Henderson BE, Ross RK, Pike MC. Toward the primary prevention of cancer. Science 1995; 254: 1131-8
26. Key TJA, Beral V. Sex hormones and cancer. In: Vainio H, Magee PN, McGregor DB, et al., editors. Mechanisms of carcinogenesis in risk identification. Lyon: IARC, 1992: 255-69
27. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990; 50: 7415-21
28. Ashby J, Tennant RW. Prediction of rodent carcinogenicity for 44 chemicals: results. Mutagenesis 1994; 9: 7-15
29. Usui T, Griffiths S, Lumley CE. Industry viewpoint: the utility of the mouse for the assessment of the carcinogenic potential of pharmaceuticals. In: D'Arcy PF, Harron DWG, editors. Proceedings of the Third International Conference on Harmonisation; Nov 1995: Yokohama, Japan. Belfast: Queen's University Press, 1996: 279-84
30. Goldsworthy TL, Reuo L, Brown K, et al. Transgenic animals in toxicology. Fundam Appl Toxicol 1994; 22: 8-19
31. Gonzalez F. Use of transgenic animals in carcinogenesis studies. Molec Carcinogen 1996; 16: 63-7
32. Tennant RW, French JE, Spalding JW. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 1995; 103: 942-50
33. Robinson D. ILSI's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol Pathol 1998. In press
34. Ashton GA, Griffiths SA, McAuslane JAN, et al. High dose selection for carcinogenicity studies - implementation of ICH guidelines during 1995 and 1996 [abstract no. 286]. Toxicol Sci 1998; 42S
35. Monro AM. The paradoxical lack of interspecies correlations between plasma concentrations and chemical carcinogenicity. Regul Toxicol Pharmacol 1993; 18: 115-35
36. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60
37. Contrera JF, Jacobs AC, Prasanna HR, et al. A systemic exposure-based alternative to maximum tolerated dose for cardnogenicity studies of human therapeutics. J Am Coll Toxicol 1995; 14: 1-10
38. Monro AM, Davies TS. High dose levels are not necessary in rodent studies to detect human carcinogens. Cancer Lett 1993; 75: 183-94
39. Davies TS, Monro AM. The case for an upper dose limit of 1000 mg/kg in rodent carcinogenicity tests. Cancer Lett 1995; 95: 69-77